Noxopharm Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

NoxopharmDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -14.4% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 5.2% pro Jahr.

Wichtige Informationen

-14.4%

Wachstumsrate der Gewinne

13.9%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	9.6%
Wachstumsrate der Einnahmen	5.2%
Eigenkapitalrendite	-184.4%
Netto-Marge	-312.9%
Letzte Ertragsaktualisierung	31 Dec 2023

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 17

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Sep 04

Aufschlüsselung der Einnahmen und Ausgaben

Wie Noxopharm Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

ASX:NOX Einnahmen, Ausgaben und Erträge (AUD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Dec 23	4	-12	5	0
30 Sep 23	5	-14	5	0
30 Jun 23	6	-15	6	0
31 Mar 23	6	-15	6	0
31 Dec 22	7	-15	7	0
30 Sep 22	6	-17	7	0
30 Jun 22	5	-19	7	0
31 Mar 22	6	-15	7	0
31 Dec 21	6	-11	6	0
30 Sep 21	6	-10	7	0
30 Jun 21	6	-9	7	0
31 Mar 21	6	-5	7	0
31 Dec 20	6	0	7	0
30 Sep 20	7	0	8	0
30 Jun 20	8	0	8	0
31 Mar 20	6	-7	9	2
31 Dec 19	4	-15	10	4
30 Sep 19	4	-13	10	5
30 Jun 19	4	-11	9	7
31 Mar 19	4	-11	9	6
31 Dec 18	3	-10	8	5
30 Sep 18	2	-14	7	4
30 Jun 18	1	-18	6	4
31 Mar 18	1	-16	5	3
31 Dec 17	1	-14	4	3
30 Sep 17	1	-8	3	2
30 Jun 17	0	-3	2	1
31 Mar 17	0	-3	2	1

Qualität der Erträge: NOX ist derzeit unrentabel.

Wachsende Gewinnspanne: NOX ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: NOX ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 14.4% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von NOX verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: NOX ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-2.6%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: NOX hat eine negative Eigenkapitalrendite (-184.44%), da es derzeit unrentabel ist.

Noxopharm Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Full year 2022 earnings released: AU$0.064 loss per share (vs AU$0.035 loss in FY 2021)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.035 loss per share (vs AU$0.002 loss in FY 2020)

Recent updates

New major risk - Market cap size

New major risk - Share price stability

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Full year 2022 earnings released: AU$0.064 loss per share (vs AU$0.035 loss in FY 2021)

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

No independent directors

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Full year 2021 earnings released: AU$0.035 loss per share (vs AU$0.002 loss in FY 2020)

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Founder exercised options to buy AU$5.5m worth of stock.

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

New 90-day high: AU$0.69

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Noxopharm Limited Provides Update on Its Ongoing New Immuno-Oncology Drug

Noxopharm Limited Announces Independent Discovery Validates Darrt Cancer Therapy

New 90-day high: AU$0.54

Noxopharm Limited Announce Partnership with Hudson Institute of Medical Research and Australian National University for the Formation of the New Australian Drug Development Company

New 90-day high: AU$0.44

Noxopharm Limited Announces the Final Patient Has Completes Treatment in the Lupin Study

Noxopharm Announces First COVID-19 Patient Treated in Veyonda Study

Noxopharm Limited Announces the Enrolment and Treatment of the First Patient into the Phase 1 NOXCOVID-1

New 90-day high: AU$0.39

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren